Compare BKU & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 2010 | 2015 |
| Metric | BKU | NVCR |
|---|---|---|
| Price | $44.82 | $15.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $51.58 | $28.08 |
| AVG Volume (30 Days) | 549.9K | ★ 1.1M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 14.61 | ★ 21.79 |
| EPS | ★ 1.79 | N/A |
| Revenue | $21,732,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $16.26 | $7.72 |
| Revenue Next Year | $4.78 | $6.74 |
| P/E Ratio | $25.25 | ★ N/A |
| Revenue Growth | 7.45 | ★ 8.28 |
| 52 Week Low | $35.10 | $9.82 |
| 52 Week High | $52.11 | $21.45 |
| Indicator | BKU | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 37.66 |
| Support Level | $44.34 | $14.84 |
| Resistance Level | $45.65 | $18.43 |
| Average True Range (ATR) | 0.92 | 0.80 |
| MACD | -0.08 | -0.27 |
| Stochastic Oscillator | 26.45 | 8.31 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.